New York, June 5, 2026, 07:05 EDT
- TCRT finished at $2.44, falling 6.9% ahead of the main U.S. session.
- Filings show the company has little cash on hand and is facing a Nasdaq equity compliance problem.
- Alaunos is looking to shift investor focus to ALN1003, an early-stage drug aimed at obesity and metabolic disorders.
Alaunos Therapeutics (TCRT) shares are looking weak going into Friday in the U.S. after dropping 6.9% to finish Thursday at $2.44. Investors are watching the company’s slim cash levels and its early-stage obesity drug program. The stock is listed on the Nasdaq Capital Market, with Friday’s session set for normal trading hours.
Alaunos is a small biotech, with a market cap near $6 million at Thursday’s close. The shares have moved between $1.67 and $6.20 in the last 52 weeks. The thin trading leaves the stock open to quick swings.
Alaunos’ investor-relations page didn’t show any new company filings after a Form 4 posted on May 27, used for insider trading disclosures. The last major update was a May 26 filing covering ALN1003, described as its oral, non-hormonal, non-incretin small-molecule drug for obesity and related metabolic problems. “Non-incretin” means it doesn’t target incretin hormone pathways like GLP-1, which is the focus for several popular obesity treatments. Alaunos
Alaunos said in a May 26 update it combined results from two non-Good Laboratory Practice mouse studies using a diet-induced obesity model. These non-GLP studies are early-stage tests that do not follow the formal quality and safety protocols set for regulatory packages. The company reported the data showed changes tied to treatment in mouse body weight, fat mass, insulin resistance, adipose signaling, and liver results. But it flagged that ALN1003 has not yet gone into human testing.
Chief Executive Holger Weis said in the release the profile was “distinctive” because treatment-linked changes showed up across a range of metabolic readouts. Weis also said the mouse data “must be interpreted with appropriate caution.” SEC
Funding is the challenge. Alaunos reported $354,000 in cash and cash equivalents as of March 31 and said its current cash runway lasts only into the second quarter of 2026. Cash runway is how long the company can keep going at its present spending pace before it needs to raise more capital.
Alaunos reported zero revenue for the first quarter and posted a net loss of $1.0 million, according to its filing. Stockholders’ equity stood at $1.29 million as of March 31, which falls short of the $2.5 million minimum needed to keep its listing on the Nasdaq Capital Market.
Alaunos got word from Nasdaq on April 9 that it was out of compliance with the rule. The company said it has until May 26 to turn in a compliance plan, but there’s no guarantee Nasdaq will accept it or that Alaunos will get back in compliance if more time is granted.
Obesity drug makers face a hard road. Alaunos has to compete with big names like Novo Nordisk and Eli Lilly, which built the market with their incretin-based drugs Wegovy and Zepbound. Cigna plans to stop paying for GLP-1 weight-loss drugs like Wegovy and Zepbound for its own staff from July 1, according to a Reuters report this week. Pricing and reimbursement questions are very much alive—even for the biggest players.
That could be part of why investors aren’t reacting much to the mouse results. Alaunos has more to do — including preclinical tests, formulation, manufacturing, and finding cash — before ALN1003 can get close to an investigational new drug filing, which is what U.S. regulators require for human studies.
Alaunos is facing a tough spot. If the company can’t get new capital, secure more time from Nasdaq, or deliver more data that meets tougher study standards, shares could come under more pressure and see less liquidity. Alaunos has also warned that if its obesity and metabolic-disorders work stalls, the board could look at shutting down and liquidating the company.
